Consequently, many HR deficient cases are identified by sequencing BRCA1/2 or PALB2, and this approach has led to initial approval of PARP inhibitors in multiple tumor types including breast, ovarian, pancreatic, and prostate cancer. The gene discussed is PARP1; the disease is Familial prostate cancer.